[Role of Interim 18F-FDG PET/CT Scanning for Diffuse Large B Cell Lymphoma in Rituximab Era -Review].

Abstract

As an important noninvasive diagnostic tool, the positron emission tomography/computed tomography (PET/CT) plays a significant role in diagnosis and therapy of patients with diffuse large B-cell lymphoma (DLBCL). PET/CT, a standard imaging tool for initial accurate staging and response assessments, has replaced conventional CT in rituximab era. In this review, the definition, interpretation method, prognostic value and risk stratification of interim PET/CT are introduced to clarify the guiding significance of PET/CT in the diagnosis and theray of DLBCL, and the application of PET/CT scanning-guided prognostic factors and response-adapted therapy for DLBCL is summarized.

• Authors: Xiao-Lin Lu, Hai-Yan Zhu, Li Yu
• Journal: Zhongguo shi yan xue ye xue za zhi (Zhongguo Shi Yan Xue Ye Xue Za Zhi) Vol. 25 Issue 4 Pg. 1241-1244 (Aug 2017) ISSN: 1009-2137 [Print] China
• PMID: 28823301 (Publication Type: Journal Article, Review)

Chemical References

• Fluorodeoxyglucose F18
• Rituximab

Topics

• Fluorodeoxyglucose F18
• Humans
• Lymphoma, Large B-Cell, Diffuse
• Positron Emission Tomography Computed Tomography
• Prognosis
• Rituximab